Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: J Immunol. 2012 Jul 6;189(4):1567–1576. doi: 10.4049/jimmunol.1103171

Figure 7. Memory CD4+ T cells expressed increased levels of miR-29b in MS patients.

Figure 7

(A) Memory CD4+CD45RO+ T cells were purified by negative selection (>95% purity) from healthy donors (HD) and MS patients. miR-29b levels were quantified using the NanoString nCounter System, which provides a digital readout of individual mature miR-29b copies in each sample. Data are categorized as all HD (n=17) and all MS (n=19), as well as stratified according to MS subtype including relapsing-remitting MS (RRMS, n=11), primary progressive MS (PPMS, n=4), and secondary progressive MS (SPMS, n=4). Lines represent mean expression. P-values were calculated by technical normalization based on positive controls, followed by a geometric mean normalization using the top 50 most highly expressed miRNAs, and a Student’s t-test for individual miRNA comparisons. (B–C) Quantification of T-bet (B) and IFN-γ (C) mRNA transcript in the purified memory T cells from (A). P-values were calculated using one-way ANOVA. (D) Resting memory T cells from a subset of HD (n=5) and MS (n=5) were reactivated with PMA and ionomycin. miR-29b levels were quantified using the NanoString nCounter System as in (A). Delta miR-29b was calculated by subtracting the activated miR-29b count from the resting memory miR-29b counts. P-value was determined using a Student’s two-tailed t-test.